RGX 314

Drug Profile

RGX 314

Alternative Names: RGX-314

Latest Information Update: 29 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator REGENXBIO
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Wet age-related macular degeneration

Most Recent Events

  • 15 Mar 2017 REGENXBIO has patents pending for RGX 314 in USA (REGENXBIO, 10-K, March 2017)
  • 01 Mar 2017 Phase-I clinical trials in Wet age-related macular degeneration in USA (Ophthalmic) (NCT03066258)
  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top